Skip to content

Data Sources and Attributions

Last updated: October 5, 2026

Whodini brings together information published by U.S. government agencies, open scientific databases, and other public sources. This page lists those sources, their license or public-domain status, and the attributions their publishers ask for.

Whodini selects, normalizes, links, and summarizes this data, so the information you see in the Service is modified from the original sources and may differ from them. Third-party data is provided "as is", without warranty, and may be incomplete or out of date. No data source, government agency, or other organization listed on this page endorses, sponsors, or is affiliated with Whodini. See Section 14 of our Terms of Service.

U.S. Food and Drug Administration

These sources are U.S. government works in the public domain. Data provided by the U.S. Food and Drug Administration (https://open.fda.gov).

  • Drugs@FDA, including the approval letters and labeling documents it links to
  • Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations)
  • Purple Book (Database of Licensed Biological Products)
  • Novel Drug Approvals and the Compilation of CDER New Molecular Entity and New Biologic Approvals
  • CBER biological approvals, including archived FDA pages
  • Breakthrough Therapy, Fast Track, and Accelerated Approval lists
  • National Drug Code (NDC) Directory, through openFDA
  • openFDA drug labeling, dedicated to the public domain under CC0 1.0
  • Unique Ingredient Identifiers (UNII)

U.S. National Library of Medicine

This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

  • DailyMed drug labeling
  • RxNorm, including ingredient identifier links that RxNorm attributes to the DrugBank vocabulary (OMx Personal Health Analytics Inc.)
  • MeSH (Medical Subject Headings)
  • ClinicalTrials.gov, described under Clinical trials below

Some terminology in the Service comes from the UMLS Metathesaurus, release 2026AA, of the U.S. National Library of Medicine, through RxNorm and the NCI Metathesaurus. Some material in the UMLS Metathesaurus is from copyrighted sources of the respective copyright holders. Users of the UMLS Metathesaurus are solely responsible for compliance with any copyright, patent or trademark restrictions and are referred to the copyright, patent or trademark notices appearing in the original sources, all of which are hereby incorporated by reference.

National Cancer Institute

  • NCI Thesaurus. The NCI Thesaurus™ is produced by the Enterprise Vocabulary Services group of the Center for Biomedical Informatics and Information Technology, National Cancer Institute, Maryland, USA. It is licensed under CC BY 4.0. Whodini uses NCI Thesaurus content in modified form.
  • NCI Metathesaurus, release 202608, built on the UMLS Metathesaurus.
  • NCI Drug Dictionary. The NCI Drug Dictionary was originally published by the National Cancer Institute.

Other U.S. government sources

  • Global Substance Registration System (GSRS), from the National Center for Advancing Translational Sciences, National Institutes of Health, developed with the U.S. Food and Drug Administration. Dedicated to the public domain under CC0 1.0.
  • Medication Reference Terminology (MED-RT), U.S. Department of Veterans Affairs, Veterans Health Administration, distributed by NCI Enterprise Vocabulary Services.
  • EDGAR company filings, U.S. Securities and Exchange Commission.

Clinical trials

Clinical trial information is from ClinicalTrials.gov, a service of the U.S. National Library of Medicine, obtained through the Aggregate Analysis of ClinicalTrials.gov (AACT) database of the Clinical Trials Transformation Initiative (CTTI). We update it from AACT's daily snapshots.

Whodini modifies this data. We keep a subset of each record (study details, brief summaries, interventions, study arms, conditions, and sponsors), standardize intervention, condition, and sponsor names, and link trials to the drugs, companies, and conditions in our databases.

The U.S. government does not review or approve the safety and science of all studies listed on ClinicalTrials.gov. The study sponsor or investigator submits information about their study and is responsible for the safety, science, and accuracy of any study they list.

Scientific databases

  • ChEMBL, from EMBL's European Bioinformatics Institute (EMBL-EBI). ChEMBL data is from http://www.ebi.ac.uk/chembl - the version of ChEMBL is chembl_37. Licensed under CC BY-SA 3.0 Unported. Whodini's ChEMBL-derived data is an adaptation of ChEMBL.
  • ChEBI, from EMBL-EBI. ChEBI data is from http://www.ebi.ac.uk/chebi - the version of ChEBI is 255. Licensed under CC BY 4.0. Whodini uses ChEBI data in modified form.
  • UniChem identifier mappings, from EMBL-EBI.
  • IUPHAR/BPS Guide to PHARMACOLOGY, from the International Union of Basic and Clinical Pharmacology and the British Pharmacological Society, version 2026.2. Contains information from IUPHAR/BPS Guide to PHARMACOLOGY, which is made available here under the Open Database License (ODbL). Its contents are licensed under CC BY-SA 4.0.
  • Open Targets Platform, release 26.06, dedicated to the public domain under CC0 1.0. Its mechanism-of-action data is derived from ChEMBL.

Company information

  • Wikidata, dedicated to the public domain under CC0 1.0.
  • Wikipedia articles, released under CC BY-SA 4.0, used as a source for company descriptions.
  • Company websites, press releases, and news coverage, which remain the property of their publishers.

Citations

  • Zdrazil B, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52(D1):D1180-D1192. doi:10.1093/nar/gkad1004
  • Malik A, et al. ChEBI: re-engineered for a sustainable future. Nucleic Acids Res. 2025. doi:10.1093/nar/gkaf1271
  • Harding SD, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2026. Nucleic Acids Res. 2026;54(D1):D1446-D1456. doi:10.1093/nar/gkaf1067
  • Buniello A, et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025;53(D1):D1467-D1475. doi:10.1093/nar/gkae1128
  • Chambers J, et al. UniChem: a unified chemical structure cross-referencing and identifier tracking system. J Cheminform. 2013;5:3. doi:10.1186/1758-2946-5-3
  • Nelson SJ, et al. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18(4):441-8. doi:10.1136/amiajnl-2011-000116

Questions

For questions about this page or about how Whodini uses a data source, contact support@whodini.ai.

Sign inGet started free